Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

360 ARTÍCULOS , VIENDO DEL 46 AL 60

Activation of the α-secretase processing of AβPP as a therapeutic approach in Alzheimer's disease

Vincent B, Govitrapong P.

J Alzheimers Dis. 2011;24 Suppl 2:75-94. doi: 10.3233/JAD-2011-110218.

Amyloid clearance as a treatment target against Alzheimer's disease

Kurz A, Perneczky R.

J Alzheimers Dis. 2011;24 Suppl 2:61-73. doi: 10.3233/JAD-2011-102139.

Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy

Plangár I, Zádori D, Klivényi P, Toldi J, Vécsei L.

J Alzheimers Dis. 2011;24 Suppl 2:199-209. doi: 10.3233/JAD-2011-110131.

Membrane anchored and lipid raft targeted β-secretase inhibitors for Alzheimer's disease therapy

Ben Halima S, Rajendran L.

J Alzheimers Dis. 2011;24 Suppl 2:143-52. doi: 10.3233/JAD-2011-110269.

Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study

Rainer M, Wuschitz A, Jagsch C, Erb C, Chirikdjian JJ, Mucke HA.

J Neural Transm (Vienna). 2011 Aug;118(8):1255-9. doi: 10.1007/s00702-011-0623-8. Epub 2011 Apr 2.

Public financial support receipt and non-medical resource utilization in Alzheimer's disease results from the PLASA study

Rapp T, Grand A, Cantet C, Andrieu S, Coley N, Portet F, Vellas B.

Soc Sci Med. 2011 Apr;72(8):1310-6. doi: 10.1016/j.socscimed.2011.02.039. Epub 2011 Mar 21.

Rehabilitating a brain with Alzheimer's: a proposal

Aranda-Abreu GE, Hernández-Aguilar ME, Manzo Denes J, García Hernández LI, Herrera Rivero M.

Clin Interv Aging. 2011;6:53-9. doi: 10.2147/CIA.S14008. Epub 2011 Feb 22.

Silencing of CDK5 as potential therapy for Alzheimer's disease

López-Tobón A, Castro-Álvarez JF, Piedrahita D, Boudreau RL, Gallego-Gómez JC, Cardona-Gómez GP.

Rev Neurosci. 2011;22(2):143-52. doi: 10.1515/RNS.2011.015.

Lack of evidence for the efficacy of memantine in mild Alzheimer disease

Schneider LS, Dagerman KS, Higgins JP, McShane R.

Arch Neurol. 2011 Aug;68(8):991-8. doi: 10.1001/archneurol.2011.69. Epub 2011 Apr 11.

[Therapeutic approaches targeting the presumed underlying pathogenic mechanisms in Alzheimer's disease]

Delrieu J, Piau A, Vellas B.

Rev Med Interne. 2011 Jun;32 Suppl 1:S22-5. doi: 10.1016/j.revmed.2011.03.005. Epub 2011 Apr 13.

Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease

Nie Q, Du XG, Geng MY.

Acta Pharmacol Sin. 2011 May;32(5):545-51. doi: 10.1038/aps.2011.14. Epub 2011 Apr 18.

Assessing family caregiver skill in managing behavioral symptoms of Alzheimer's disease

Farran CJ, Fogg LG, McCann JJ, Etkin C, Dong X, Barnes LL.

Aging Ment Health. 2011 May;15(4):510-21. doi: 10.1080/13607863.2010.536140.

Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads

Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A.

Expert Opin Biol Ther. 2011 Jun;11(6):679-86. doi: 10.1517/14712598.2011.579099. Epub 2011 Apr 19.

Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors

Mancini F, De Simone A, Andrisano V.

Anal Bioanal Chem. 2011 Jun;400(7):1979-96. doi: 10.1007/s00216-011-4963-x. Epub 2011 Apr 20.

Solanezumab for Alzheimer's disease

Samadi H, Sultzer D.

Expert Opin Biol Ther. 2011 Jun;11(6):787-98. doi: 10.1517/14712598.2011.578573. Epub 2011 Apr 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias